Janice Lu

3.6k total citations
50 papers, 1.3k citations indexed

About

Janice Lu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Janice Lu has authored 50 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Janice Lu's work include Advanced Breast Cancer Therapies (23 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (10 papers). Janice Lu is often cited by papers focused on Advanced Breast Cancer Therapies (23 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (10 papers). Janice Lu collaborates with scholars based in United States, Spain and France. Janice Lu's co-authors include John J. Chen, Xiaolei Zhu, Shenhong Wu, Andrzej P. Kudelka, Sara A. Hurvitz, Yu-Waye Chu, Barbara Tong, Edith A. Perez, Chunyan Song and Giulia Bianchi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Janice Lu

47 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janice Lu United States	17	830	398	373	305	264	50	1.3k
Noam Pondé Belgium	19	981 1.2×	372 0.9×	324 0.9×	488 1.6×	212 0.8×	52	1.4k
Zsuzsanna Kahán Hungary	24	827 1.0×	415 1.0×	386 1.0×	608 2.0×	262 1.0×	100	1.7k
Aranzazu Fernández-Martínez Spain	13	717 0.9×	281 0.7×	517 1.4×	583 1.9×	153 0.6×	47	1.5k
Julia Lawrence United States	16	656 0.8×	279 0.7×	271 0.7×	175 0.6×	294 1.1×	31	1.3k
Akiyo Yoshimura Japan	18	508 0.6×	279 0.7×	377 1.0×	352 1.2×	93 0.4×	67	1.2k
Patricia B. Trusk United States	8	450 0.5×	114 0.3×	374 1.0×	120 0.4×	134 0.5×	13	786
Varun Monga United States	19	372 0.4×	355 0.9×	283 0.8×	134 0.4×	171 0.6×	81	1.1k
Burkhard Riemann Germany	20	265 0.3×	123 0.3×	317 0.8×	257 0.8×	329 1.2×	62	1.2k
Hui Lin Chua United States	19	394 0.5×	259 0.7×	494 1.3×	297 1.0×	540 2.0×	29	1.3k

Countries citing papers authored by Janice Lu

Since Specialization

Citations

This map shows the geographic impact of Janice Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice Lu more than expected).

Fields of papers citing papers by Janice Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice Lu. The network helps show where Janice Lu may publish in the future.

Co-authorship network of co-authors of Janice Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Janice Lu. A scholar is included among the top collaborators of Janice Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janice Lu. Janice Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Çil, Onur, A.S. Verkman, Matilda F. Chan, et al.. (2024). Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody–Drug Conjugates (ADCs). Current Ophthalmology Reports. 12(2). 13–22. 7 indexed citations

Ring, Alexander, Tania B. Porras, Guang‐Biao Zhou, et al.. (2024). Integrated Proteogenomic Analysis Reveals Distinct Potentially Actionable Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Subtypes. Cancers. 16(3). 516–516. 1 indexed citations

Bardia, Aditya, Javier Cortés, François‐Clément Bidard, et al.. (2024). Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical Cancer Research. 30(19). 4299–4309. 33 indexed citations

Lu, Janice, et al.. (2024). Current and future immunotherapy for breast cancer. Journal of Hematology & Oncology. 17(1). 131–131. 23 indexed citations

Jayachandran, Priya, Francesca Battaglin, Annika Lenz, et al.. (2023). Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions. Oncogene. 42(9). 627–637. 17 indexed citations

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

Jayachandran, Priya, Yasmine Baca, Joanne Xiu, et al.. (2023). Abstract P4-08-06: Clock Genes in Breast Cancer. Cancer Research. 83(5_Supplement). P4–8. 1 indexed citations

Shishido, Stephanie N., Liya Xu, Lisa Welter, et al.. (2022). Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib. npj Breast Cancer. 8(1). 22–22. 17 indexed citations

Bardia, Aditya, Janice Lu, Virginia Kaklamani, et al.. (2020). 179TiP EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine therapy for ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy. Annals of Oncology. 31. S80–S80. 2 indexed citations

10.

Spears, Angela Page, et al.. (2019). Psychoeducation Interventions for Parents and Teachers of Children and Adolescents with ADHD: a Systematic Review of the Literature. Journal of Developmental and Physical Disabilities. 32(2). 257–292. 40 indexed citations

11.

Lee, Kyuwan, Irene Kang, Wendy J. Mack, et al.. (2019). Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study. Breast Cancer Research and Treatment. 177(2). 477–485. 37 indexed citations

12.

Wang, Yunchao, Tao Sun, Lijun Sheng, et al.. (2018). Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis. Oncology Research and Treatment. 41(7-8). 450–455. 15 indexed citations

13.

D'souza, Anishka, Darcy Spicer, & Janice Lu. (2018). Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. Journal of Hematology & Oncology. 11(1). 80–80. 44 indexed citations

14.

Zamagni, Claudio, Mario Campone, Ursa Brown‐Glaberman, et al.. (2018). Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. Annals of Oncology. 29. viii710–viii710.

15.

Wang, Yunchao, Janice Lu, Yanping Li, et al.. (2015). Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study. OncoTargets and Therapy. 8. 3337–3337. 8 indexed citations

16.

Lu, Janice. (2015). Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. Journal of Hematology & Oncology. 8(1). 98–98. 60 indexed citations

17.

Hurvitz, Sara A., Luc Dirix, Judit Kocsis, et al.. (2013). Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 31(9). 1157–1163. 302 indexed citations

18.

Mu, Ying, et al.. (2013). Targeted therapy for HER2 positive breast cancer. Journal of Hematology & Oncology. 6(1). 38–38. 61 indexed citations

19.

Lu, Janice, Tina Fan, Qiang Zhao, et al.. (2009). Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. International Journal of Cancer. 126(3). 669–683. 124 indexed citations

20.

Wu, Shenhong, John J. Chen, Andrzej P. Kudelka, Janice Lu, & Xiaolei Zhu. (2008). Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. The Lancet Oncology. 9(2). 117–123. 305 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact